These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 18065132

  • 1. Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken.
    Whiteside DP, Barker IK, Conlon PD, Tesoro A, Thiessen JJ, Mehren KG, Jacobs RM, Spino M.
    J Avian Med Surg; 2007 Jun; 21(2):110-20. PubMed ID: 18065132
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
    Whiteside DP, Barker IK, Conlon PD, Tesoro A, Thiessen JJ, Mehren KG, Jacobs RM, Spino M.
    J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.
    Whiteside DP, Barker IK, Mehren KG, Jacobs RM, Conlon PD.
    J Zoo Wildl Med; 2004 Mar; 35(1):40-9. PubMed ID: 15193072
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP.
    Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
    [Abstract] [Full Text] [Related]

  • 5. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [Abstract] [Full Text] [Related]

  • 6. The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
    Soulières D, Mercier-Ross J, Fradette C, Rozova A, Tsang YC, Tricta F.
    Ann Hematol; 2022 Mar; 101(3):533-539. PubMed ID: 34981144
    [Abstract] [Full Text] [Related]

  • 7. The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.
    Song D, Zhao L, Li Y, Hadziahmetovic M, Song Y, Connelly J, Spino M, Dunaief JL.
    Invest Ophthalmol Vis Sci; 2014 Jun 26; 55(7):4525-32. PubMed ID: 24970260
    [Abstract] [Full Text] [Related]

  • 8. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
    Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, Koren G, Brittenham GM, Gordeuk VR.
    Am J Trop Med Hyg; 1998 Mar 26; 58(3):358-64. PubMed ID: 9546419
    [Abstract] [Full Text] [Related]

  • 9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 26; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 10. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S.
    Am J Hematol; 2013 Apr 26; 88(4):251-60. PubMed ID: 23460233
    [Abstract] [Full Text] [Related]

  • 11. Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
    Fradette C, Pichette V, Sicard É, Stilman A, Jayashankar S, Tsang YC, Spino M, Tricta F.
    Br J Clin Pharmacol; 2016 Oct 26; 82(4):994-1001. PubMed ID: 27276421
    [Abstract] [Full Text] [Related]

  • 12. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.
    Rodrat S, Yamanont P, Tankanitlert J, Chantraraksri U, Fucharoen S, Morales NP.
    Pharmacology; 2012 Oct 26; 90(1-2):88-94. PubMed ID: 22759897
    [Abstract] [Full Text] [Related]

  • 13. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.
    Hadziahmetovic M, Song Y, Wolkow N, Iacovelli J, Grieco S, Lee J, Lyubarsky A, Pratico D, Connelly J, Spino M, Harris ZL, Dunaief JL.
    Invest Ophthalmol Vis Sci; 2011 Feb 16; 52(2):959-68. PubMed ID: 21051716
    [Abstract] [Full Text] [Related]

  • 14. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.
    al-Refaie FN, De Silva CE, Wonke B, Hoffbrand AV.
    J Clin Pathol; 1995 Feb 16; 48(2):110-4. PubMed ID: 7745107
    [Abstract] [Full Text] [Related]

  • 15. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A.
    J Pediatr Hematol Oncol; 2010 Nov 16; 32(8):601-5. PubMed ID: 20921906
    [Abstract] [Full Text] [Related]

  • 16. The efficacy of oral deferiprone in acute iron poisoning.
    Berkovitch M, Livne A, Lushkov G, Segal M, Talmor C, Bentur Y, Klein J, Koren G.
    Am J Emerg Med; 2000 Jan 16; 18(1):36-40. PubMed ID: 10674529
    [Abstract] [Full Text] [Related]

  • 17. Long-term treatment with deferiprone in a L1 veteran.
    Meo A, Ruggeri A, La Rosa MA, Zanghì L, Kordes U, Fischer R.
    Eur J Haematol; 2005 Jun 16; 74(6):523-5. PubMed ID: 15876257
    [Abstract] [Full Text] [Related]

  • 18. Effect of oral iron chelator L1 on iron absorption in man.
    Dresow B, Fischer R, Nielsen P, Gabbe EE, Piga A.
    Ann N Y Acad Sci; 1998 Jun 30; 850():466-8. PubMed ID: 9668586
    [No Abstract] [Full Text] [Related]

  • 19. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
    Chuansumrit A, Songdej D, Sirachainan N, Wongwerawattanakoon P, Kadegasem P, Sasanakul W.
    Paediatr Int Child Health; 2016 Aug 30; 36(3):209-13. PubMed ID: 26052612
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L.
    Clin Pharmacol Ther; 1990 Sep 30; 48(3):255-61. PubMed ID: 2401124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.